Gilead
Sciences, Inc. (NASDAQ:GILD) slid 0.75% to $37.08. The
52-week range of the stock is $31.73-$49.50.
Gilead
Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops
and commercializes therapeutics. The Company has operations in North America,
Europe and Australia. The Company’s products include Truvada, Atripla, Viread,
Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston.
Human
Genome Sciences (NASDAQ:HGSI) fell 3.87% to $24.10. The
52-week range of the stock is $20.56-$34.49.
Human
Genome Sciences (HGS) is a commercially focused biopharmaceutical company. The
Company has three products in late-stage clinical development: BENLYSTA for
systemic lupus erythematosus (SLE), ZALBIN for chronic hepatitis C, and
raxibacumab for inhalation anthrax.
MannKind
Corporation (NASDAQ:MNKD) surged 4.74% to $7.03. The 52-week range of the
stock is $4.76-$11.12. The stock is down more than 19% year-to-date.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today.
For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
